Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer

OBJECTIVES: The purpose of this study was to determine the relationship between carbohydrate antigen (CA) 19-9 levels and outcome in patients with borderline resectable pancreatic cancer treated with neoadjuvant therapy (NT). METHODS: This study included all patients with borderline resectable pancr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Tzeng, Ching-Wei D, Balachandran, Aparna, Ahmad, Mediha, Lee, Jeffrey E, Krishnan, Sunil, Wang, Huamin, Crane, Christopher H, Wolff, Robert A, Varadhachary, Gauri R, Pisters, Peter W T, Aloia, Thomas A, Vauthey, Jean-Nicolas, Fleming, Jason B, Katz, Matthew H G
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Ltd 2014
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008161/
https://ncbi.nlm.nih.gov/pubmed/23991810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hpb.12154
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires